Earth Science Tech Inc. (OTC: ETST) is entering a new phase of disciplined growth, marked by expanding margins, optimized cash generation, and a shift toward a more shareholder-focused public company model. The company reported third fiscal quarter 2026 revenue of $8.4 million, a 14.1% increase year-over-year, and gross profit rose to $6.4 million, expanding gross margins to 76.3% from 69.2% in the prior year, highlighting improved operating leverage across its portfolio.
ETST has announced governance reforms and cost initiatives expected to generate approximately $1.4 million in annualized savings, which the company projects will drive over 40% net income growth. These measures align with the company's strategy to accelerate profitability and enhance shareholder value. The governance transformation focuses on improving oversight and operational efficiency, underscoring ETST's commitment to long-term sustainable growth.
The company's performance in the fiscal third quarter ended December 31, 2025, reflects its ability to execute on growth while managing costs effectively. The gross margin expansion indicates improved pricing power and cost management across its business lines. Investors seeking the latest news and updates on ETST can find them in the company's newsroom at https://ibn.fm/ETST.
BioMedWire (BMW), a specialized communications platform focusing on the Biotechnology, Biomedical Sciences, and Life Sciences sectors, notes that ETST's announcement is part of a broader trend among small-cap companies to adopt more rigorous governance and cost-control measures. BMW is one of over 75 brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions.
ETST's strategic initiatives are expected to position the company for improved profitability and cash generation. The projected net income growth of over 40% signals strong earnings momentum, supported by the cost savings and governance enhancements. The company's move toward a more disciplined operating model reflects a commitment to delivering shareholder value through operational excellence and strategic growth.
For more information about BioMedWire and its services, visit https://www.BioMedWire.com. The full terms of use and disclaimers applicable to all content provided by BMW are available on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.
